Related Projects

Throughout the course of the project we will engage with other projects that are involved in similar studies.


REDDSTAR is an EU funded project which will develop and test stromal cell therapy to treat for diabetes mellitus. The objective is to control blood glucose while also addressing a range of diabetic complications. ADIPOA-2 partners NUI Galway and Pintail also collaborate on REDDSTAR.


ADIPOA-2 partners NUI Glaway and Pintail Limited participate in the FP7-funded project VISICORT. The project will design and initiate an optimised clinical trial strategy of immunomodulatory stromal stem cell therapy in high-risk human corneal transplant recipients.


MERLIN explores exciting new opportunities in stromal cell therapy R&D, while making important contributions to the treatment of currently intractable inflammatory and immune mediated liver diseases. ADIPOA-2 partner Pintail is also involved in MERLIN.


ADIPOA-2 partners NUI Galway and Pintail are collaborators in the Horizon 2020 project NEPHSTROM. The project will carry out a first in man Phase 1b/2a clinical trial of a novel stromal cell therapy for diabetic kidney disease.


The ADIPOA project, which involved a number of the ADIPOA-2 partners, conducted initial research on the use of autologous adipose stem cells to treat osteoarthritis. ADIPOA carried out a Phase 1 clinical trial, which provided essential data for ADIPOA-2.


The goal of VascuBone is to develop a ‘toolbox’ for bone regeneration. The toolbox will include a variation of biocompatible biomaterials and cell types, FDA approved growth factors, material modification technologies, simulation and analytical tools like molecular imaging based in vivo diagnostics which can be combined for the medical need of a specific patient.


RESPINE will develop a rigorously proven, effective treatment of degenerative disc disease (DDD). Via a multicentre, randomized, controlled, phase 2b clinical trial including 112 patients with DDD, RESPINE will assess the efficacy of an allogenic intervertebral mesenchymal stem cell (MSC)-based therapy. The consortium aims to provide new knowledge on immune response & safety associated with allogeneic BM-MSC intradiscal injection. This simple procedure will be cost-effective, and minimally invasive.


The SCIENCE project will conduct a multicentre, double-blind placebo-controlled trial with allogeneic adipose-derived stromal cells (CSCC_ASCs) to improve myocardial function in patients with ischemic heart disease and heart failure. In addition, SCIENCE will establish a manufacturing facility for centralised production of allogeneic CSCC_ASCs, and financial health care data to demonstrate the impact of implementing treatment with the proposed new CSCC_ASC product. The project will evaluate advanced existing and new imaging techniques in order to more precisely guide the delivery of stem cells.


STARSTEM is poised to revolutionise regenerative medicine by providing an unprecedented understanding of how cellular therapies actually work.

STARSTEM brings together leaders in the nano-materials, regenerative medicine, and bio-imaging fields from across Europe. Using fundamental advances in the physics of imaging to validate stem cell treatments for arthritis, the project results will allow researchers and eventually, clinicians, to detect and measure the healing effects of novel stem cell therapies where they occur. Understanding the dynamics and distribution of mesenchymal stem cells will enable such treatments to be optimized.